• Jay H Traverse, Timothy D Henry, Carl J Pepine, James T Willerson, David X M Zhao, Stephen G Ellis, John R Forder, R David Anderson, Antonis K Hatzopoulos, Marc S Penn, Emerson C Perin, Jeffrey Chambers, Kenneth W Baran, Ganesh Raveendran, Charles Lambert, Amir Lerman, Daniel I Simon, Douglas E Vaughan, Dejian Lai, Adrian P Gee, Doris A Taylor, Christopher R Cogle, James D Thomas, Rachel E Olson, Sherry Bowman, Judy Francescon, Carrie Geither, Eileen Handberg, Casey Kappenman, Lynette Westbrook, Linda B Piller, Lara M Simpson, Sarah Baraniuk, Catalin Loghin, David Aguilar, Sara Richman, Claudia Zierold, Daniel B Spoon, Judy Bettencourt, Shelly L Sayre, Rachel W Vojvodic, Sonia I Skarlatos, David J Gordon, Ray F Ebert, Minjung Kwak, Lemuel A Moyé, Robert D Simari, and Cardiovascular Cell Therapy Research Network (CCTRN).
• Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis, Minnesota, USA.
• JAMA. 2012 Dec 12; 308 (22): 2380-9.

ContextWhile the delivery of cell therapy after ST-segment elevation myocardial infarction (STEMI) has been evaluated in previous clinical trials, the influence of the timing of cell delivery on the effect on left ventricular function has not been analyzed.ObjectivesTo determine the effect of intracoronary autologous bone marrow mononuclear cell (BMC) delivery after STEMI on recovery of global and regional left ventricular function and whether timing of BMC delivery (3 days vs 7 days after reperfusion) influences this effect.Design, Setting, And PatientsA randomized, 2 × 2 factorial, double-blind, placebo-controlled trial, Timing In Myocardial infarction Evaluation (TIME) enrolled 120 patients with left ventricular dysfunction (left ventricular ejection fraction [LVEF] ≤ 45%) after successful primary percutaneous coronary intervention (PCI) of anterior STEMI between July 17, 2008, and November 15, 2011, as part of the Cardiovascular Cell Therapy Research Network sponsored by the National Heart, Lung, and Blood Institute.InterventionsIntracoronary infusion of 150 × 106 BMCs or placebo (randomized 2:1) within 12 hours of aspiration and cell processing administered at day 3 or day 7 (randomized 1:1) after treatment with PCI.Main Outcome MeasuresThe primary end points were change in global (LVEF) and regional (wall motion) left ventricular function in infarct and border zones at 6 months measured by cardiac magnetic resonance imaging and change in left ventricular function as affected by timing of treatment on day 3 vs day 7. The secondary end points included major adverse cardiovascular events as well as changes in left ventricular volumes and infarct size.ResultsThe mean (SD) patient age was 56.9 (10.9) years and 87.5% of participants were male. At 6 months, there was no significant increase in LVEF for the BMC group (45.2% [95% CI, 42.8% to 47.6%] to 48.3% [95% CI, 45.3% to 51.3%) vs the placebo group (44.5% [95% CI, 41.0% to 48.0%] to 47.8% [95% CI, 43.4% to 52.2%]) (P = .96). There was no significant treatment effect on regional left ventricular function observed in either infarct or border zones. There were no significant differences in change in global left ventricular function for patients treated at day 3 (−0.9% [95% CI, −6.6% to 4.9%], P = .76) or day 7 (1.1% [95% CI, −4.7% to 6.9%], P = .70). The timing of treatment had no significant effect on regional left ventricular function recovery. Major adverse events were rare among all treatment groups.ConclusionAmong patients with STEMI treated with primary PCI, the administration of intracoronary BMCs at either 3 days or 7 days after the event had no significant effect on recovery of global or regional left ventricular function compared with placebo.Trial Registrationclinicaltrials.gov Identifier: NCT00684021.

18 keywords...

hide…